Dr. Jeffrey White is an expert in transplant anesthesiology and non-operating room anesthesiology for procedures such as colonoscopy. He is fellowship trained in liver transplant anesthesia. Dr. White is an associate professor of anesthesiology, medical director of non-OR anesthesia and associate medical director of adult GI endoscopy in the College of Medicine.
Areas of Expertise (5)
Technology in Anesthesiology
Non-operating Room Anesthesiology
Effects of a Single Rapid Infusion System on Platelet Function in Stored Whole Blood: An Ex Vivo StudyCureus
Joshua W. Sappenfield, et al.
Rapid infusion systems (RIS) are used to warm and rapidly infuse crystalloids and blood products. Current guidelines do not approve of platelet transfusion through a RIS, but data supporting these guidelines are scarce. Our hypothesis was that an infusion of whole blood through a RIS would degrade platelet quantity, impede viscoelastic clot strength, and inhibit platelet aggregation response to adenosine diphosphate pathway (ADP) activation.
Sugammadex and labetalol precipitationJournal of Clinical Anesthesia
Kevin R. Olsen, et al.
Sugammadex sodium is a colorless to slightly yellow-brown, modified γ-cyclodextran provided in pH-adjusted aqueous solution and approved for reversal of rocuronium bromide and vecuronium bromide. The prescribing information notes to “ensure the infusion line is adequately flushed between the administration of sugammadex and other drugs,” but only specifically lists verapamil, ondansetron, and ranitidine as physically incompatible.
The rise, fall, and future direction of computer-assisted personalized sedationDrugs in Anesthesia
James F. Martin, et al.
The first computer-assisted personalized sedation (CAPS) device was developed to address the growing demand for routine endoscopy procedures in the United States in the early 2000s. This review will describe the environment that gave rise to CAPS and summarize the design of that first device. It will then discuss the market forces that led to the fall of CAPS, with sales of the device ending 2 years after commercialization.